Monocyte flow cytometry: designing panels around what the marker means

Building a panel that means something

1. Write the gating strategy before choosing fluorophores. Decide the order of exclusions and inclusions on paper: debris, doublets, dead cells, lineage exclusions, then the positive definitions. The strategy determines which markers must be bright and which can tolerate a dim channel, and that is what should drive fluorophore assignment.
2. Put the dim and the rare on the bright detectors. Antigens expressed at low density and populations present at low frequency need the brightest available fluorophores on the cleanest detectors. Highly expressed lineage markers can sit anywhere. Getting this backwards is the most common reason a panel underperforms its design.
3. Control for what handling does to the marker. Several activation markers appear within minutes of manipulation and some surface antigens are cleaved by the enzymes used to dissociate tissue. Fix the handling protocol, keep it identical across groups, and where possible confirm with an antibody clone whose epitope survives the treatment.
4. Exclude before you include. Populations defined by the absence of other lineages need those exclusion channels to be reliable, because a leaky dump channel contaminates the population of interest with whatever it failed to remove. Spend detector quality on exclusions, not only on the markers of interest.
5. Use full minus one controls, not isotypes. Where a boundary must be drawn, a control lacking one colour from the full panel shows where spread from every other channel puts the edge. Isotype controls do not address spillover spread and routinely place gates in the wrong position.
6. Record clone, lot and titration with the protocol. Two antibodies against the same target with different clones are different reagents. Titrate each on your own cells, record the titre, and treat a clone change as a protocol change requiring re titration.

Subsets exist on a continuum, gates do not

Monocyte subsets, activation states and differentiation stages are continuous distributions, and the gate that separates them is a convention. That is workable provided the convention is fixed, documented and applied identically across every sample in a study, and it is a serious problem when gates are drawn per sample by eye.

Where the boundary matters, anchor it with a control rather than with judgement: an unstimulated sample, a full minus one control or a reference bead set. A gate that moves with the operator produces differences that are about the operator.

Handling artefacts masquerade as biology

Time at room temperature, the choice of anticoagulant, a freeze thaw cycle and the enzyme used to release cells from tissue all change surface marker expression, and they change it consistently enough to look like a real group difference when one arm of a study is processed differently from another.

Randomise processing across groups where you can, process within a fixed window, and record the handling with the data. Most irreproducible immunophenotyping traces back to this rather than to the panel.

What to standardise across a laboratory

One dissociation protocol per tissue, one titration record per clone, one gating template per panel, and one instrument configuration with regular performance tracking. Those four items make results from different people and different months comparable.

They also make an experiment auditable. When a result is questioned, the ability to show the titration, the configuration and the template is what distinguishes an answer from an argument.

A langerin antibody and the cell it defines

Langerin is the lectin that marks Langerhans cells, so a langerin antibody separates them from the other dendritic populations in skin and mucosa, which is a distinction the broader myeloid markers cannot make. It is intracellular as well as surface, so permeabilisation changes the reading, and the clone has to be validated in the format used. Species differences in expression are substantial.

A cd1a antibody beside it in the same panel

CD1a is the other Langerhans cell marker and is read with langerin rather than instead of it, since agreement between two markers is what makes the identification. A cd1a antibody is also used in pathology on sections, where the epitope has to survive fixation, and a clone validated only for flow cytometry is not evidence that it stains tissue. Both markers appear on a subset of dermal cells too.

A cd64 antibody and the activation it reports on neutrophils

CD64 is constitutive on monocytes and macrophages and is induced on neutrophils during infection, which is the clinical reading, so a cd64 antibody is quantified as a ratio against a reference population rather than as a positive or negative. Because it is an Fc receptor, it binds antibody by design, so blocking and an isotype control are part of the method rather than optional.

A cd169 antibody and the macrophage subset it marks

CD169, also called siglec-1, marks specific tissue macrophage populations and is interferon inducible on blood monocytes, which makes a cd169 antibody both a subset marker and a response readout. Which of the two a figure means has to be stated, because the same stain supports either claim only with the right control. It binds sialylated ligands, so unrelated background is common.

An arg1 antibody and the polarisation it is read as

Arginase 1 is used as a marker of one macrophage state, and the marker is far more informative in mouse than in human, where expression differs, so an arg1 antibody validated in one species proves nothing in the other. It is cytoplasmic, so permeabilisation is required for flow cytometry, and a stimulated positive control is what makes a shift in a dim population believable.

An ly6c antibody and a mouse only distinction

Ly6C separates mouse monocyte subsets and has no human counterpart, so an ly6c antibody belongs only in mouse panels and its human analogue question is answered with CD14 and CD16 instead. The antibody cross reacts with the related Ly6G unless the clone is specific, which is exactly the distinction a monocyte and neutrophil panel rests on, so the clone rather than the catalogue name is what to record.

Common questions

Why do monocyte markers define different cells in different papers?

Because a marker is only interpretable inside a gating strategy. The same antigen appears on several lineages, and what identifies a population is the combination and the exclusions, not any single channel.

Can a published panel be used as is?

As a starting point only. Instrument configuration, fluorophore availability, sample type and handling all differ, and every antibody still needs titrating on your own cells. Published panels transfer the logic, not the settings.

What about markers that dissociation destroys?

Check whether the target is sensitive to the enzyme in use, and if it is, either change the dissociation method, choose a clone against a resistant epitope, or stop treating that marker as quantitative in dissociated tissue.

How many colours does a panel really need?

As many as the exclusions and subsets require and no more. Every added colour adds spread to the others, so a well designed panel with fewer parameters frequently resolves rare populations better than a larger one designed by accumulation.

Browse by service class

• Compare Gene synthesis on advertised prices